Ascendis Pharma A/S (ASND)
229.24
+6.55
(+2.94%)
USD |
NASDAQ |
Oct 09, 16:00
229.24
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Cash from Operations (Quarterly) : 327.52M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 327.52M |
| March 31, 2026 | -9.033M |
| December 31, 2025 | 85.47M |
| September 30, 2025 | 1.757M |
| June 30, 2025 | -9.477M |
| March 31, 2025 | -15.06M |
| December 31, 2024 | -86.07M |
| September 30, 2024 | -61.36M |
| June 30, 2024 | -65.68M |
| March 31, 2024 | -110.25M |
| December 31, 2023 | -39.69M |
| September 30, 2023 | -137.00M |
| June 30, 2023 | -167.47M |
| March 31, 2023 | -157.77M |
| December 31, 2022 | -140.17M |
| September 30, 2022 | -97.40M |
| June 30, 2022 | -132.79M |
| March 31, 2022 | -146.72M |
| December 31, 2021 | -141.77M |
| September 30, 2021 | -115.39M |
| June 30, 2021 | -138.71M |
| March 31, 2021 | -98.31M |
| December 31, 2020 | -106.18M |
| September 30, 2020 | -67.46M |
| June 30, 2020 | -62.34M |
| Date | Value |
|---|---|
| March 31, 2020 | -73.58M |
| December 31, 2019 | -54.41M |
| September 30, 2019 | -67.10M |
| June 30, 2019 | -5.985M |
| March 31, 2019 | -69.41M |
| December 31, 2018 | -41.36M |
| September 30, 2018 | -54.35M |
| June 30, 2018 | -23.60M |
| March 31, 2018 | -45.15M |
| December 31, 2017 | -29.39M |
| September 30, 2017 | -29.72M |
| June 30, 2017 | -25.66M |
| March 31, 2017 | -22.55M |
| December 31, 2016 | -18.67M |
| September 30, 2016 | -17.29M |
| June 30, 2016 | -14.64M |
| March 31, 2016 | -16.40M |
| December 31, 2015 | -11.17M |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | -9.830M |
| September 30, 2014 | -4.498M |
| June 30, 2014 | -6.615M |
| March 31, 2014 | -3.468M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 168.11M |
| Novo Nordisk A/S | 8.364B |
| Evaxion AS | -- |
| Genmab A/S | 51.04M |
| Zealand Pharma A/S | 63.85M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -3.268M |
| Cash from Financing (Quarterly) | -53.34M |
| Free Cash Flow | 388.83M |
| Free Cash Flow Per Share (Quarterly) | 4.740 |
| Free Cash Flow to Equity (Quarterly) | 842.38M |
| Free Cash Flow to Firm (Quarterly) | 338.61M |
| Free Cash Flow Yield | 2.66% |